Research area:\u00a0<\/em><\/strong>http:\/\/suvalab.mgh.harvard.edu<\/a><\/p>\n The Suv\u00e0 laboratory is focused on the biology of brain tumors, in particular diffuse gliomas in adults and children. We dissect how cellular heterogeneity and plasticity contribute to tumor properties. We study primary human samples at single-cell resolution and establish genetically and epigenetically relevant cellular models from patient tumors. We model how brain cancer cells exploit their plasticity to establish distinct epigenetic programs. We seek to identify common programs that would offer novel therapeutic options in these dismal diseases.<\/p>\n Dr. Mario Suva trained in Switzerland, where\u00a0 he also received his PhD for work in the biology of cancer stem cells in gliomas and sarcomas. He is an Assistant Professor of Pathology at Harvard Medical School where he also serves as a faculty member for the Biological and Biomedical Science Program and for the Harvard Stem Cell Institute. Additionally, he is a member of the Neuro-oncology Program at the Harvard Cancer Center and of the Epigenomics, Cancer and Cell Circuits Programs at the Broad Institute. He has received multiple awards including the Howard Goodman Award (2017), the Weil Award (2014) for best work in experimental neuropathology by the American Association of Neuropathologists and the Adult Basic Research Award from the Society for Neuro-oncology.<\/p>\n Laboratory of Genetics Spring Colloquium Series 2019 Research area:\u00a0http:\/\/suvalab.mgh.harvard.edu The Suv\u00e0 laboratory is focused on the biology of brain tumors, in particular diffuse gliomas in adults and children. We dissect how cellular heterogeneity and plasticity …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0},"tags":[],"tribe_events_cat":[109],"acf":[],"_links":{"self":[{"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tribe_events\/10674"}],"collection":[{"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tribe_events"}],"about":[{"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/types\/tribe_events"}],"author":[{"embeddable":true,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/comments?post=10674"}],"version-history":[{"count":2,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tribe_events\/10674\/revisions"}],"predecessor-version":[{"id":10677,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tribe_events\/10674\/revisions\/10677"}],"wp:attachment":[{"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/media?parent=10674"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tags?post=10674"},{"taxonomy":"tribe_events_cat","embeddable":true,"href":"https:\/\/wwwtest.cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tribe_events_cat?post=10674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Brief bio:<\/h3>\n
Publications (selected):<\/h3>\n
\n\n
\n Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
\nKeskin DB et al. Nature. 2019 Jan;565(7738):234-239. doi: 10.1038\/s41586-018-0792-9.<\/td>\n<\/tr>\n\n Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
\nBunse L, et al.,\u00a0 Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038\/s41591-018-0095-6.<\/td>\n<\/tr>\n\n A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.
\nGriveau A et al., Cancer Cell. 2018 May 14;33(5):874-889.e7. doi: 10.1016\/j.ccell.2018.03.020.<\/td>\n<\/tr>\n\n Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.
\nFilbin MG, \u2026, Suv\u00e0 ML.
\nScience. 2018 Apr 20;360(6386):331-335. doi: 10.1126\/science.aao4750.<\/td>\n<\/tr>\n\n Toward methylation-based classification of central nervous system tumors.
\nHegi ME, Kleihues P, Wen PY, Suv\u00e0 ML.
\nNeuro Oncol. 2018 Apr 9;20(5):579-581. doi: 10.1093\/neuonc\/noy023.<\/td>\n<\/tr>\n\n Dissecting human gliomas by single-cell RNA sequencing.
\nTirosh I, Suv\u00e0 ML.
\nNeuro Oncol. 2018 Jan 10;20(1):37-43. doi: 10.1093\/neuonc\/nox126. Review.<\/td>\n<\/tr>\n\n Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing.
\nTang Q, Iyer S, Lobbardi R, Moore JC, Chen H, Lareau C, Hebert C, Shaw ML, Neftel C, Suva ML, Ceol CJ, Bernards A, Aryee M, Pinello L, Drummond IA, Langenau DM.
\nJ Exp Med. 2017 Oct 2;214(10):2875-2887. doi: 10.1084\/jem.20170976. E<\/td>\n<\/tr>\n\n Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.
\nYu D, Khan OF, Suv\u00e0 ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS.
\nProc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156. doi: 10.1073\/pnas.1701911114.<\/td>\n<\/tr>\n\n Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
\nVenteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suv\u00e0 ML.
\nScience. 2017 Mar 31;355(6332). pii: eaai8478. doi: 10.1126\/science.aai8478.<\/td>\n<\/tr>\n\n Purine synthesis promotes maintenance of brain tumor initiating cells in glioma.
\nWang X, Yang K, Xie Q, Wu Q, Mack SC, Shi Y, Kim LJY, Prager BC, Flavahan WA, Liu X, Singer M, Hubert CG, Miller TE, Zhou W, Huang Z, Fang X, Regev A, Suv\u00e0 ML, Hwang TH, Locasale JW, Bao S, Rich JN.
\nNat Neurosci. 2017 May;20(5):661-673. doi: 10.1038\/nn.4537.<\/td>\n<\/tr>\n\n Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
\nLiau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suv\u00e0 ML, Patel AP, Bernstein BE.
\nCell Stem Cell. 2017 Feb 2;20(2):233-246.e7. doi: 10.1016\/j.stem.2016.11.003.<\/td>\n<\/tr>\n\n IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.
\nDegrauwe N, Suv\u00e0 ML, Janiszewska M, Riggi N, Stamenkovic I.
\nGenes Dev. 2016 Nov 15;30(22):2459-2474. Review.<\/td>\n<\/tr>\n\n Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.
\nTirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A, Suv\u00e0 ML.
\nNature. 2016 Nov 10;539(7628):309-313. doi: 10.1038\/nature20123.<\/td>\n<\/tr>\n\n The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.
\nDegrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, Riggi N, Suv\u00e0 ML, Paro R, Stamenkovic I.
\nCell Rep. 2016 May 24;15(8):1634-47. doi: 10.1016\/j.celrep.2016.04.086.<\/td>\n<\/tr>\n\n Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time.
\nFilbin MG, Suv\u00e0 ML.
\nAnnu Rev Pathol. 2016 May 23;11:497-521. doi: 10.1146\/annurev-pathol-012615-044208. Review.<\/td>\n<\/tr>\n\n Insulator dysfunction and oncogene activation in IDH mutant gliomas.
\nFlavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suv\u00e0 ML, Bernstein BE.
\nNature. 2016 Jan 7;529(7584):110-4. doi: 10.1038\/nature16490. Epub 2015 Dec 23.<\/td>\n<\/tr>\n\n Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
\nFlynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suv\u00e0 ML, Benes CH, Haber DA, Boussin FD, Zou L.
\nScience. 2015 Jan 16;347(6219):273-7. doi: 10.1126\/science.1257216.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"